(Q43824367)

English

Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.

scientific article published in November 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

prostate carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

E Calvo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

J Cortés

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

J Rodríguez

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

M Sureda

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

C Beltrán

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

J Rebollo

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

R Martínez-Monge

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

J M Berián

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

A Brugarolas

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

language of work or name

0 references

publication date

1 November 2001

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

92

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

2435-2443

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Prostate cancer: screening, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Suramin binds to platelet-derived growth factor and inhibits its biological activity

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2435%3A%3AAID-CNCR1593%3E3.0.CO%3B2-O

21 January 2018

Identifiers

10.1002/1097-0142(20011101)92:9<2435::AID-CNCR1593>3.0.CO;2-O

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11745301%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43824367&oldid=2103675759"